Format

Send to

Choose Destination
Adv Healthc Mater. 2017 Nov;6(22). doi: 10.1002/adhm.201700808. Epub 2017 Sep 8.

An Inexpensive, Point-of-Care Urine Test for Bladder Cancer in Patients Undergoing Hematuria Evaluation.

Author information

1
Department of Chemical and Petroleum Engineering, University of Pittsburgh, 15213, Pittsburgh, PA, USA.
2
Department of Urology, University of Pittsburgh Medical Center, 15213, Pittsburgh, PA, USA.
3
Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, 15213, Pittsburgh, PA, USA.
4
Department of Bioengineering, University of Pittsburgh, 15213, Pittsburgh, PA, USA.
5
Department of Pharmaceutical Sciences, University of Pittsburgh, 15213, Pittsburgh, PA, USA.
6
Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA.
7
Department of Ophthalmology, University of Pittsburgh, 15213, Pittsburgh, PA, USA.
8
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Abstract

Although hematuria (blood in urine) is the most common symptom of bladder cancer, 70-98% of hematuria cases are benign. These hematuria patients unnecessarily undergo costly, invasive, and expensive evaluation for bladder cancer. Therefore, there remains a need for noninvasive office-based tests that can rapidly and reliably rule out bladder cancer in patients undergoing hematuria evaluation. Herein, a clinical assay for matrix metalloproteinases ("Ammps") is presented, which generates a visual signal based on the collagenase activity (in urine of patients) on the Ammps substrates. Ammps substrates are generated by crosslinking gelatin with Fe(II) chelated alginate nanoparticles, which precipitate in urine samples. The cleavage of gelatin-conjugated alginate (Fe(II)) nanoparticles by collagenases generates free-floating alginate (Fe(II)) nanoparticles that participate in Fenton's reaction to generate a visual signal. In a pilot study of 88 patients, Ammps had 100% sensitivity, 85% specificity, and a negative predictive value (NPV) of 100% for diagnosing bladder cancer. This high NPV can be useful in ruling out bladder cancer in patients referred for hematuria evaluation.

KEYWORDS:

MMPs; bladder cancer; cost-effective; diagnostics; urine test

PMID:
28885787
DOI:
10.1002/adhm.201700808
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center